/ACAD
ACAD Stock - ACADIA Pharmaceuticals Inc.
Healthcare|BiotechnologyNASDAQ
$27.16+2.11%
+$0.56 (+2.11%) • Dec 19
84
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.94
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).91
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.93
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+20.4%upside
Target: $32.70
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ACAD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$26.89 – $27.43
TARGET (TP)$32.71
STOP LOSS$24.99
RISK/REWARD1:2.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.67
52W High$27.73
52W Low$13.40
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $957.80M | $726.44M | $517.24M | $484.14M | $441.75M |
| Gross Profit | $875.96M | $680.71M | $507.07M | $465.00M | $421.20M |
| Gross Margin | 91.5% | 93.7% | 98.0% | 96.0% | 95.3% |
| Operating Income | $230.79M | $-73,379,000 | $-223,596,000 | $-170,439,000 | $-286,586,000 |
| Net Income | $226.45M | $-61,286,000 | $-215,975,000 | $-167,870,000 | $-281,584,000 |
| Net Margin | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% |
| EPS | $1.37 | $-0.37 | $-1.34 | $-1.05 | $-1.79 |
Company Overview
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
12
55%
Hold / Neutral
8
36%
Sell / Underperform
2
9%
Analyst Consensus🟡 Mixed
12 Bullish10 Neutral/Bearish
Price Targets
$27
Average Target
↓ 2.0% Downside
Now
$10
Low
$27
Average
$40
High
Based on 24 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 21st 2025 | Citigroup | Initiation | Buy | $33 |
| May 21st 2025 | Deutsche Bank | Upgrade | Buy | $35 |
| February 11th 2025 | Deutsche Bank | Initiation | Hold | $22 |
| January 3rd 2025 | Guggenheim | Downgrade | Neutral | $20← $23 |
| October 10th 2024 | Raymond James | Resumed | Market Perform | - |
| August 7th 2024 | Morgan Stanley | Downgrade | Equal Weight | $20← $28 |
| June 27th 2024 | BMO Capital Markets | Initiation | Outperform | $31 |
| March 12th 2024 | Needham | Reiterated | Buy | $32← $36 |
| March 12th 2024 | Mizuho | Downgrade | Neutral | $25← $39 |
| January 30th 2024 | Robert W. Baird | Initiation | Outperform | $40 |
| January 24th 2024 | Needham | Upgrade | Buy | $37 |
| December 19th 2023 | Morgan Stanley | Upgrade | Overweight | $40← $31 |
| December 14th 2023 | Deutsche Bank | Downgrade | Hold | $25 |
| December 13th 2023 | Citigroup | Initiation | Buy | $38 |
| December 12th 2023 | Deutsche Bank | Initiation | Buy | $25 |
Earnings History & Surprises
ACADBeat Rate
72%
Last 18 quarters
Avg Surprise
+23.0%
EPS vs Estimate
Beats / Misses
13/5
Last 12 quarters
Latest EPS
$0.26
Q4 2025
EPS Surprise History
Q1 24
-6.7%
$0.28vs$0.30
Q2 24
+100.0%
$0.10vs$0.05
Q3 24
+11.1%
$0.20vs$0.18
Q4 24
+42.9%
$0.20vs$0.14
Q1 25
+30.8%
$0.17vs$0.13
Q2 25
+10.0%
$0.11vs$0.10
Q3 25
+14.3%
$0.16vs$0.14
Q4 25
+85.7%
$0.26vs$0.14
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $0.14 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.14 | $0.26 | +85.7% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.14 | $0.16 | +14.3% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.10 | $0.11 | +10.0% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $0.13 | $0.17 | +30.8% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.14 | $0.20 | +42.9% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.18 | $0.20 | +11.1% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $0.05 | $0.10 | +100.0% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $0.30 | $0.28 | -6.7% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.43 | $-0.40 | +7.0% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-0.12 | $0.01 | +108.3% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.21 | $-0.27 | -28.6% | ✗ MISS |
Q1 2023 | Feb 27, 2023 | $-0.25 | $-0.26 | -4.0% | ✗ MISS |
Q4 2022 | Nov 2, 2022 | $-0.18 | $-0.17 | +5.6% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.25 | $-0.21 | +16.0% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.49 | $-0.70 | -42.9% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.24 | $-0.27 | -12.5% | ✗ MISS |
Q4 2021 | Nov 8, 2021 | $-0.27 | $-0.09 | +66.7% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-0.30 | $-0.27 | +10.0% | ✓ BEAT |
Latest News
HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $37
📈 PositiveBenzinga•Dec 15, 2025, 04:00 PM
Acadia Pharmaceuticals Announces FDA Approval Of DAYBUE STIX For Oral Solution For Treatment Of Rett Syndrome
📈 PositiveBenzinga•Dec 12, 2025, 01:01 PM
Stifel Maintains Hold on ACADIA Pharmaceuticals, Raises Price Target to $25
➖ NeutralBenzinga•Dec 11, 2025, 01:15 PM•Also:
Mizuho Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $29
➖ NeutralBenzinga•Dec 2, 2025, 03:18 PM
JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $31
➖ NeutralBenzinga•Nov 17, 2025, 05:23 PM
RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $32
➖ NeutralBenzinga•Nov 6, 2025, 03:35 PM
Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $29
📈 PositiveBenzinga•Nov 6, 2025, 10:07 AM
CORRECTION: ACADIA Pharmaceuticals Q3 Adj. EPS $0.26 Beats $0.15 Estimate, Sales $278.633M Beat $276.466M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 10:54 PM
ACADIA Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 sales results and raised its FY25 sales guidance.
📈 PositiveBenzinga•Nov 5, 2025, 10:09 PM
ACADIA Pharmaceuticals Raises FY2025 Sales Guidance from $1.045B-$1.095B to $1.070B-$1.095B vs $1.072B Est
📈 PositiveBenzinga•Nov 5, 2025, 09:44 PM
ACADIA Pharmaceuticals Q3 EPS $0.42 May Not Be Comparable To $0.14 Estimate, Sales $278.633M Beat $276.466M Estimate
➖ NeutralBenzinga•Nov 5, 2025, 09:43 PM
Citigroup Initiates Coverage On ACADIA Pharmaceuticals with Buy Rating, Announces Price Target of $33
📈 PositiveBenzinga•Oct 21, 2025, 10:51 AM•Also:
Acadia Pharmaceuticals To Present ACP-711 And ACP-204 Updates, NUPLAZID Analysis At 2025 International Parkinson's Congress October 5-9, 2025
➖ NeutralBenzinga•Oct 2, 2025, 01:06 PM
JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $33
➖ NeutralBenzinga•Sep 29, 2025, 12:10 PM•Also:
Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $28
➖ NeutralBenzinga•Sep 24, 2025, 02:54 PM
Acadia Pharmaceuticals shares are trading lower after its Phase 3 COMPASS PWS trial of intranasal carbetocin in Prader-Willi syndrome failed to meet the primary endpoint.
📉 NegativeBenzinga•Sep 24, 2025, 11:37 AM
Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Sep 24, 2025, 11:25 AM
Acadia's Phase 3 COMPASS PWS Trial Of Intranasal Carbetocin Fails To Meet Primary Endpoint In Prader-Willi Hyperphagia
📉 NegativeBenzinga•Sep 24, 2025, 11:02 AM
Trading Halt: Halted at 6:55:13 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Sep 24, 2025, 10:55 AM
Acadia Pharma Announces Publication Of Interim Results From LOTUS Study On DAYBUE For Rett Syndrome In Developmental Medicine And Child Neurology Journal
➖ NeutralBenzinga•Sep 12, 2025, 08:07 PM
Frequently Asked Questions about ACAD
What is ACAD's current stock price?
ACADIA Pharmaceuticals Inc. (ACAD) is currently trading at $27.16 per share. The stock has moved +2.11% today.
What is the analyst price target for ACAD?
The average analyst price target for ACAD is $32.71, based on 1 analyst.
What sector is ACADIA Pharmaceuticals Inc. in?
ACADIA Pharmaceuticals Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ACAD's market cap?
ACADIA Pharmaceuticals Inc. has a market capitalization of $4.59 billion, making it a mid-cap company.
Does ACAD pay dividends?
No, ACADIA Pharmaceuticals Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADMA
ADMA Biologics, Inc.
$19.58
Mkt Cap: $4.7B
BLTE
Belite Bio, Inc
$156.00
Mkt Cap: $5.4B
CRNX
Crinetics Pharmaceuticals, Inc.
$48.01
Mkt Cap: $4.6B
DYN
Dyne Therapeutics, Inc.
$19.85
Mkt Cap: $2.8B
IMVT
Immunovant, Inc.
$26.68
Mkt Cap: $4.7B
LGND
Ligand Pharmaceuticals Incorporated
$200.33
Mkt Cap: $3.9B
MIRM
Mirum Pharmaceuticals, Inc.
$77.74
Mkt Cap: $3.8B
PRAX
Praxis Precision Medicines, Inc.
$272.92
Mkt Cap: $5.8B
SLNO
Soleno Therapeutics, Inc.
$47.85
Mkt Cap: $2.6B
VKTX
Viking Therapeutics, Inc.
$35.19
Mkt Cap: $4.0B
Explore stocks similar to ACAD for comparison